Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

00:00

The Probability of Success for Pelabricid

Pelabricid has a very different risk structure and profile than what you're typically used to evaluating. Most analysts put 50% probability success on their there. They all have a peak sales that's not like crazily off ours, right? I mean, somewhere around a billion. We actually think the odds are higher based on the base rate and the data and everything.

Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner